Chief Development AdvisorBrenda Cooperstone, MD has over 25 years of pharmaceutical drug development experience. Previously, she was Senior Vice President and Chief Development Officer for Rare Disease at Pfizer Inc. As Chief Development Officer, she was responsible for the strategic growth and advancement of the Pfizer development portfolio for the Rare Disease Business, building advanced technology platforms like Gene Therapy. Prior to this role, Brenda held varied leadership positions in both Clinical Development and Global Medical Affairs with oversight of a wide range of therapeutic areas, including both small and large molecules in early through late phase development and in-line support. She currently serves as an Independent Director on the Boards of Senti Biosciences and Gandeeva Therapeutics. Brenda received her M.D. from McGill University, completed her residency in pediatrics at the Montreal Children’s Hospital, her clinical fellowship in pediatric nephrology at Children’s Hospital of Philadelphia and a research fellowship at the University of Pennsylvania, Renal Electrolyte Division. She is certified by the American Board of Pediatrics and Pediatric Nephrology and the Royal College of Physicians and Surgeons of Canada, Pediatrics.